ADPKD Guide
Readable, evidence-first ADPKD treatment, symptoms, diet, trials, and research updates for patients, families, and clinicians.
Last sweep: Jun 1, 2026
What’s New Methodology References Support GitHub
Patient Guide Treatment Trials Cure
More
What’s New Newly Diagnosed Tolvaptan Diet Symptoms Clinicians Methodology References Support
ADPKD Guide Evidence-first

ADPKD treatment, research, diet, trials, and symptoms in one readable place

A mobile-first, evidence-first guide for people who want clear ADPKD guidance grounded in actual evidence.

Last reviewed: June 1, 2026

How to use this site

  • Who it is for: patients, families, and clinicians who want evidence-weighted ADPKD guidance without miracle-claim noise.
  • What it uses: trial data, guidelines, and tracked research updates ranked by evidence strength.
  • What it is not: personal medical advice or a cure-claims funnel dressed up as education.
  • How fresh it is: each page shows the latest review date pulled from the research pipeline.

Research

Trials, cure research, and what changed recently.

Research Trials

Latest tracked movement

  • Key new evidence this run , GLPG2737 / CFTR inhibition failed in the phase 2a MANGROVE study: it did not reduce htTKV growth or slow eGFR decline versus placebo in rapidly progressive ADPKD (PMID42201338).
  • Four-track review outcome
  • What strengthened , The negative CFTR result cleaned up a weak hypothesis.